Tests a treatment plan in children with high-risk acute lymphoblastic leukemia
Tests chemotherapy plans in children newly diagnosed with high-risk leukemia.
Plain-language title generated from the registry record
Registry title: Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Key facts
- Where
- Incheon, Seoul, Suwon, and Yangsan, South KoreaSee the 9 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 19 years old?
Source: NCT06184009, who can take part
Where in South Korea
- Inha University HospitalIncheon, South KoreaNot yet recruiting
- Asan Medical CenterSeoul, South KoreaTaking people
- Korea University Anam HospitalSeoul, South KoreaNot yet recruiting
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
- Seoul saint Mary's HospitalSeoul, South KoreaTaking people
- Severance hospitalSeoul, South KoreaTaking people
- Ajou University HospitalSuwon, South KoreaTaking people
- Pusan National University Yangsan HospitalYangsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jae Wook Lee
- Trial code
- NCT06184009
- Record updated
- 29 July 2026
- Original description
* Clinical and genetic factors consistent with High risk : Induction → ConsolidationRead full original descriptionShow less
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia-prospective, Nationwide, Multi-center Study
* Clinical and genetic factors consistent with High risk : Induction → Consolidation
1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3. BM MRD ≥ 0.01% after Consolidation
<!-- -->
1. T cell ALL : Change to very high risk regimen 2. Pre-B ALL : IM #1 → Intensification
1. BM MRD \< 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance 2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen
* Difference in the number of \'interim maintenance(IM)\' and \'delayed intensification(DI)\' is important for chemotherapies based on MRD.
<Inclusion Criteria>; Age: 1year~19years of age at diagnosis; Patients who are newly diagnosed Pre-B ALL and meet one of the following criteria; High-risk group according to the National Cancer Institute (NCI)/Rome: Age greater than or equal to 10 years and less than 19 years at diagnosis, or white blood cell count greater than or equal to 50 x 10\^9/L at diagnosis; If extra-bone marrow lesions are identified at the time of diagnosis, Central nervous system involvement (CNS3) or testicular involvement; High-risk gene variants:; KMT2A rearrangement intrachromosomal amplification of chromosome 21 (iAMP21); ● If subjects are under the age of 10 at the time of diagnosis and took steroids for more than 24 hours within two weeks before the diagnosis, the risk group will be determined by the presence of a whole blood test within three days before starting steroids. If a whole blood test is performed within three days before beginning steroids, the risk group will be assessed based on the white blood cell count in the test. If there is no whole blood test before starting steroids, subjects are classified as a high-risk group. If subjects are ten or older at diagnosis, pre-diagnosis steroid treatment will not affect the risk classification; Newly diagnosed T cell ALL; <Exclusion Criteria>; Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia; Patients with Down syndrome; potential of pregnancy or during pregnancy (patients of childbearing age need adequate contraception for the duration of the trial); Patients who have already received steroid treatment for newly diagnosed ALL specified in the above selection criteria or chemotherapies more than one intrathecal cytarabine treatment; Participating in an interventional clinical trial other than this research.